G6PD and G6PD deficiency: These drugs were chosen due to their significant risk of triggering hemolysis in G6PD-deficient individuals, their diverse range of potential mechanisms for inducing hemolysis (including both drug metabolite-induced oxidative stress and potential non-immune mediated membrane damage), and their clinical relevance in regions where G6PD deficiency and the diseases they treat (malaria and leprosy) are prevalent.